Biosimilars Council Commends Nixing ‘Arbitrary’ Interchangeability Designation
The Proposal Was Included In President Biden’s FY2025 Budget Request
The Biosimilars Council agreed with the US president’s proposal to remove the “unnecessary” designation for biosimilars, which strengthens the ongoing debate over the need for interchangeability.
